Company:  SIGA TECHNOLOGIES INC (SIGA)
Form Type:  10-Q
Filing Date:  11/6/2013 
CIK:  0001010086 
Address:  27 EAST 62ND STREET 
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$6.90  
Change: 
0.19 (2.83%)  
Trade Time: 
Jun 22  
Market Cap: 
$545.46M
Trade SIGA now with 

© 2018  
Description of Business
SIGA Technologies, Inc. is referred to throughout this report as "SIGA," "the Company," "we" or "us." We are a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. A new drug application ("NDA") for TPOXX® was submitted to the United States Food & Drug Administration ("FDA") in December 2017. In February 2018, the Company received notice that the FDA granted priority review of the NDA and that the FDA's target final action date is August 8, 2018. While TPOXX® is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being delivered to the U.S.
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1 - Condensed Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sale of Equity Securities and Use of ...
      Item 3. Defaults upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 31.2
    Certification by Chief Financial Officer Pursuant to
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO